Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database
Aim: To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV). Methods: We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to seve...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Clinical Virology Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667038025000158 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850128686940946432 |
|---|---|
| author | Manami Yoshida Nao Taguchi Yi Piao Rikisha Gupta Jami Peters Mazin Abdelghany Mel Chiang Chen-Yu Wang Mark Berry Hiroshi Yotsuyanagi |
| author_facet | Manami Yoshida Nao Taguchi Yi Piao Rikisha Gupta Jami Peters Mazin Abdelghany Mel Chiang Chen-Yu Wang Mark Berry Hiroshi Yotsuyanagi |
| author_sort | Manami Yoshida |
| collection | DOAJ |
| description | Aim: To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV). Methods: We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to severe COVID-19, and who received ≥ 1 dose of RDV between October 2021 and September 2022, using a Japanese medical claims database. All-cause mortality, progression to severe COVID-19, and hospital discharge/recovery status were evaluated up to 56 days from the index date defined as RDV initiation. Results: The analysis included 502 patients. The mean (SD) age at index was 74.4 (12.5) years. Median (Q1–Q3) time to RDV initiation was 2.0 (1.0–3.0) days from hospital admission; median treatment duration was 5.0 (3.0–5.0) days. At index date, 36.85 % of patients had moderate I disease (hospitalized without oxygen support), 58.96 % had moderate II disease (non-invasive positive pressure ventilation, low/high-flow oxygen), and 4.18 % had severe disease (ICU admission, mechanical ventilation, or extracorporeal membrane oxygenation). Proportion of patients with all-cause mortality was 11.16 % (95 % CI, 8.54–14.24) and 13.15 % (10.32–16.42) by 28 and 56 days. At 28 days, 12.35 % (9.60–15.55) of patients had disease progression, and 68.13 % (63.85–72.19) had recovery. Conclusion: Most patients were elderly and required oxygen support when initiating RDV. The majority of patients received RDV within 3 days of hospitalization and recovered by 28 days. The study provides insight into outcomes in Japanese COVID-19 patients with DM treated with RDV in inpatient settings. |
| format | Article |
| id | doaj-art-202e2b73b8114bfd82e2a57ddf4c821e |
| institution | OA Journals |
| issn | 2667-0380 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical Virology Plus |
| spelling | doaj-art-202e2b73b8114bfd82e2a57ddf4c821e2025-08-20T02:33:12ZengElsevierJournal of Clinical Virology Plus2667-03802025-06-015210021610.1016/j.jcvp.2025.100216Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims databaseManami Yoshida0Nao Taguchi1Yi Piao2Rikisha Gupta3Jami Peters4Mazin Abdelghany5Mel Chiang6Chen-Yu Wang7Mark Berry8Hiroshi Yotsuyanagi9Gilead Sciences K.K., 16F Grantokoyo Southtower, 1-9-2, Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan; Corresponding author at: Gilead Sciences K.K., 16F Grantokyo Southtower, 1-9-2, Marunouchi, Chiyoda-ku, Tokyo 100-6616, Japan.Gilead Sciences K.K., 16F Grantokoyo Southtower, 1-9-2, Marunouchi, Chiyoda-ku, Tokyo 100-6616, JapanGilead Sciences K.K., 16F Grantokoyo Southtower, 1-9-2, Marunouchi, Chiyoda-ku, Tokyo 100-6616, JapanGilead Sciences Inc., 333, Lakeside Drive, Foster City, CA 94404, USAGilead Sciences Inc., 333, Lakeside Drive, Foster City, CA 94404, USAGilead Sciences Inc., 333, Lakeside Drive, Foster City, CA 94404, USAGilead Sciences Inc., 333, Lakeside Drive, Foster City, CA 94404, USAGilead Sciences Inc., 333, Lakeside Drive, Foster City, CA 94404, USAGilead Sciences Inc., 333, Lakeside Drive, Foster City, CA 94404, USADepartment of Infectious Diseases and Applied Immunology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, JapanAim: To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV). Methods: We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to severe COVID-19, and who received ≥ 1 dose of RDV between October 2021 and September 2022, using a Japanese medical claims database. All-cause mortality, progression to severe COVID-19, and hospital discharge/recovery status were evaluated up to 56 days from the index date defined as RDV initiation. Results: The analysis included 502 patients. The mean (SD) age at index was 74.4 (12.5) years. Median (Q1–Q3) time to RDV initiation was 2.0 (1.0–3.0) days from hospital admission; median treatment duration was 5.0 (3.0–5.0) days. At index date, 36.85 % of patients had moderate I disease (hospitalized without oxygen support), 58.96 % had moderate II disease (non-invasive positive pressure ventilation, low/high-flow oxygen), and 4.18 % had severe disease (ICU admission, mechanical ventilation, or extracorporeal membrane oxygenation). Proportion of patients with all-cause mortality was 11.16 % (95 % CI, 8.54–14.24) and 13.15 % (10.32–16.42) by 28 and 56 days. At 28 days, 12.35 % (9.60–15.55) of patients had disease progression, and 68.13 % (63.85–72.19) had recovery. Conclusion: Most patients were elderly and required oxygen support when initiating RDV. The majority of patients received RDV within 3 days of hospitalization and recovered by 28 days. The study provides insight into outcomes in Japanese COVID-19 patients with DM treated with RDV in inpatient settings.http://www.sciencedirect.com/science/article/pii/S2667038025000158COVID-19Diabetes mellitusDisease progressionMortalityRecoveryRemdesivir |
| spellingShingle | Manami Yoshida Nao Taguchi Yi Piao Rikisha Gupta Jami Peters Mazin Abdelghany Mel Chiang Chen-Yu Wang Mark Berry Hiroshi Yotsuyanagi Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database Journal of Clinical Virology Plus COVID-19 Diabetes mellitus Disease progression Mortality Recovery Remdesivir |
| title | Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database |
| title_full | Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database |
| title_fullStr | Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database |
| title_full_unstemmed | Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database |
| title_short | Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database |
| title_sort | patient characteristics treatment patterns and clinical outcomes of remdesivir in hospitalized covid 19 patients with diabetes mellitus on insulin a large scale data analysis using a japanese claims database |
| topic | COVID-19 Diabetes mellitus Disease progression Mortality Recovery Remdesivir |
| url | http://www.sciencedirect.com/science/article/pii/S2667038025000158 |
| work_keys_str_mv | AT manamiyoshida patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT naotaguchi patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT yipiao patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT rikishagupta patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT jamipeters patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT mazinabdelghany patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT melchiang patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT chenyuwang patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT markberry patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase AT hiroshiyotsuyanagi patientcharacteristicstreatmentpatternsandclinicaloutcomesofremdesivirinhospitalizedcovid19patientswithdiabetesmellitusoninsulinalargescaledataanalysisusingajapaneseclaimsdatabase |